**CMS (Centers for Medicare & Medicaid Services)** plays a pivotal role in shaping healthcare policy and access in the United States, overseeing vital programs that impact millions of Americans. Recently, CMS has been at the center of significant discussions surrounding drug pricing and healthcare regulations, particularly with its proposed modifications to orphan drug exemptions in drug-pricing pilots. Analysts warn that exempting these rare disease therapies could negate substantial savings, sparking intense lobbying from biotech firms aiming to protect their interests. Further, the finalized CMS rule on gender-affirming care is poised to withstand legal challenges more effectively than previous policies, indicating a shift towards more inclusive healthcare practices. Meanwhile, innovations like Humata Health aim to tackle the $30 billion prior authorization market, potentially benefiting from CMS's regulatory expansions. With a new framework for breakthrough device coverage also in the works, the implications for market access and healthcare delivery are profound. These developments suggest a landscape ripe with opportunities for stakeholders, inviting proactive engagement in shaping the future of healthcare.